X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (59) 59
female (41) 41
adult (39) 39
male (37) 37
exanthema (32) 32
middle aged (24) 24
index medicus (21) 21
adolescent (16) 16
child (16) 16
child, preschool (11) 11
exanthema - chemically induced (11) 11
measles (11) 11
aged (10) 10
immunization (10) 10
vaccination (10) 10
immunology (9) 9
infant (9) 9
risk factors (9) 9
diseases (8) 8
infectious diseases (8) 8
measles - epidemiology (8) 8
lupus erythematosus, systemic - ethnology (7) 7
rheumatology (7) 7
systemic lupus erythematosus (7) 7
asian continental ancestry group (6) 6
china - ethnology (6) 6
epidemiology (6) 6
exanthema - etiology (6) 6
lupus (6) 6
microbiology (6) 6
prevalence (6) 6
travel (6) 6
treatment outcome (6) 6
abridged index medicus (5) 5
classification (5) 5
disease outbreaks (5) 5
exanthema - diagnosis (5) 5
exanthema - ethnology (5) 5
fever - etiology (5) 5
infections (5) 5
medicine, general & internal (5) 5
pregnancy (5) 5
research (5) 5
young adult (5) 5
age (4) 4
cohort (4) 4
cohort studies (4) 4
diagnosis, differential (4) 4
disease transmission (4) 4
emigration and immigration (4) 4
lupus erythematosus, systemic - immunology (4) 4
measles - transmission (4) 4
medicine & public health (4) 4
mutation (4) 4
oncology (4) 4
photosensitivity (4) 4
public health (4) 4
retrospective studies (4) 4
revised criteria (4) 4
time factors (4) 4
3 ethnic-groups (3) 3
adopted children (3) 3
adoption (3) 3
adults (3) 3
anemia (3) 3
animals (3) 3
anthropology (3) 3
anti-hiv agents - adverse effects (3) 3
antibodies (3) 3
antiretroviral therapy (3) 3
autoantibodies (3) 3
biopsy (3) 3
children (3) 3
congenital rubella syndrome (3) 3
deoxycytidine - analogs & derivatives (3) 3
deoxycytidine - therapeutic use (3) 3
dermatology (3) 3
dosage (3) 3
double-blind method (3) 3
drug administration schedule (3) 3
drug therapy (3) 3
epidemics (3) 3
exanthema - genetics (3) 3
exanthema - pathology (3) 3
fever (3) 3
gene (3) 3
immunity (3) 3
internal medicine (3) 3
japan (3) 3
lupus erythematosus, systemic - complications (3) 3
measles - diagnosis (3) 3
measles - ethnology (3) 3
measles - prevention & control (3) 3
mortality (3) 3
patient outcomes (3) 3
pharmacology & pharmacy (3) 3
philippines - ethnology (3) 3
public, environmental & occupational health (3) 3
rash (3) 3
regression analysis (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9787, pp. 238 - 246
Summary Background Efavirenz with tenofovir-disoproxil-fumarate and emtricitabine is a preferred antiretroviral regimen for treatment-naive patients infected... 
Internal Medicine | LAMIVUDINE | MEDICINE, GENERAL & INTERNAL | EFFICACY | SAFETY | COMBINATION THERAPY | GUIDELINES | PROTEASE-INHIBITOR | ANTIRETROVIRAL THERAPY | NEVIRAPINE | REGIMENS | Rilpivirine | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | Middle Aged | Male | Anti-HIV Agents - administration & dosage | Nitriles - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Adenine - adverse effects | Adenine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Reverse Transcriptase Inhibitors - therapeutic use | Acquired Immunodeficiency Syndrome - virology | Acquired Immunodeficiency Syndrome - ethnology | Emtricitabine | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Organophosphonates - therapeutic use | HIV-1 - drug effects | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | Organophosphonates - adverse effects | Benzoxazines - adverse effects | Treatment Outcome | HIV-1 - genetics | Acquired Immunodeficiency Syndrome - drug therapy | Adenine - administration & dosage | Benzoxazines - therapeutic use | Organophosphonates - administration & dosage | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Aged | Mutation | Nitriles - adverse effects | Viral Load - drug effects | Deoxycytidine - analogs & derivatives | Nitriles - therapeutic use | Dosage and administration | Efavirenz | Patient outcomes | Clinical trials | Antiretroviral drugs | Drug therapy | Human immunodeficiency virus--HIV
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9787, pp. 229 - 237
Summary Background The non-nucleoside reverse transcriptase inhibitor (NNRTI), rilpivirine (TMC278; Tibotec Pharmaceuticals, County Cork, Ireland), had... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | ZIDOVUDINE | COMBINATION THERAPY | ACTIVE ANTIRETROVIRAL THERAPY | EMTRICITABINE | PROTEASE-INHIBITOR | CYSTATIN-C | CREATININE | DAILY LAMIVUDINE | NEVIRAPINE | TENOFOVIR | Rilpivirine | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | Middle Aged | Male | Anti-HIV Agents - administration & dosage | Nitriles - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Nucleotides - therapeutic use | Adenine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Reverse Transcriptase Inhibitors - therapeutic use | Acquired Immunodeficiency Syndrome - virology | Acquired Immunodeficiency Syndrome - ethnology | Emtricitabine | Nucleosides - therapeutic use | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Organophosphonates - therapeutic use | HIV-1 - drug effects | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | Benzoxazines - adverse effects | Treatment Outcome | HIV-1 - genetics | Acquired Immunodeficiency Syndrome - drug therapy | Benzoxazines - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Mutation | Nitriles - adverse effects | Viral Load - drug effects | Deoxycytidine - analogs & derivatives | Nitriles - therapeutic use | Evaluation | Patient outcomes | Clinical trials | Dosage and administration | Drug therapy | HIV infection | Design | Antiretroviral drugs | Corporate sponsorship | Human immunodeficiency virus--HIV | Technological change | Research | Clinical medicine | Drugs | RNA-directed DNA polymerase | Exanthema | antiretroviral therapy | Lamivudine | Lipids | Nucleotides | Regression analysis | Efavirenz | CD4 antigen | nucleosides | Algorithms | Hospitals | non-nucleoside reverse transcriptase inhibitors | Abacavir | Zidovudine | Pharmaceuticals
Journal Article
Journal Article
BMJ Open, ISSN 2044-6055, 06/2016, Volume 6, Issue 6, p. e011714
ObjectivesBevacizumab and erlotinib inhibit different tumour growth pathways, and both exhibit beneficial effects in the treatment of non-small-cell lung... 
non-small cell lung cancer | bevacizumab | meta-analysis | erlotinib | PHASE IIIB TRIAL | 1ST-LINE TREATMENT | PLACEBO | MONOCLONAL-ANTIBODY | ANTITUMOR-ACTIVITY | COMBINATION | CHEMOTHERAPY | MEDICINE, GENERAL & INTERNAL | THERAPY | DOUBLE-BLIND | DISEASE PROGRESSION | Smoking - adverse effects | Lung Neoplasms - drug therapy | Lung Neoplasms - ethnology | Bevacizumab - therapeutic use | Age Factors | Bevacizumab - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Diarrhea - chemically induced | Antineoplastic Agents - adverse effects | Exanthema - chemically induced | Oceanic Ancestry Group | Carcinoma, Non-Small-Cell Lung - pathology | Erlotinib Hydrochloride - adverse effects | Carcinoma, Non-Small-Cell Lung - ethnology | Disease-Free Survival | Antineoplastic Agents, Immunological - adverse effects | Asian Continental Ancestry Group | Antineoplastic Agents, Immunological - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Erlotinib Hydrochloride - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Lung cancer | Diarrhea | Metastasis | Cancer therapies | Meta-analysis | Studies | Quality | Response rates | Libraries | Mutation | Clinical medicine | Pharmaceutical industry | Vascular endothelial growth factor | Tumors
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 2/2012, Volume 69, Issue 2, pp. 457 - 465
We conducted phase I and tolerability studies to determine the maximum tolerated dose (MTD) and recommended dose of nab-paclitaxel when administered weekly... 
Medicine & Public Health | Weekly administration | Phase I study | Cancer Research | Oncology | Ocular toxicity | Pharmacology/Toxicology | Albumin-bound paclitaxel | CREMOPHOR-FREE | FORMULATION | WOMEN | THERAPY | ONCOLOGY | TAXOL | PHARMACOLOGY & PHARMACY | ABI-007 | III TRIAL | Neoplasms - metabolism | Nausea - chemically induced | Area Under Curve | Albumin-Bound Paclitaxel | Humans | Middle Aged | Male | Metabolic Clearance Rate | Paclitaxel - pharmacokinetics | Nanoparticles - adverse effects | Diarrhea - chemically induced | Breast Neoplasms - metabolism | Dose-Response Relationship, Drug | Albumins - therapeutic use | Neoplasm Metastasis | Albumins - adverse effects | Neoplasms - ethnology | Exanthema - chemically induced | Nanoparticles - therapeutic use | Adult | Female | Antineoplastic Agents, Phytogenic - therapeutic use | Antineoplastic Agents, Phytogenic - pharmacokinetics | Breast Neoplasms - ethnology | Antineoplastic Agents, Phytogenic - adverse effects | Drug Administration Schedule | Japan | Paclitaxel - adverse effects | Treatment Outcome | Breast Neoplasms - drug therapy | Paclitaxel - therapeutic use | Neoplasms - drug therapy | Asian Continental Ancestry Group | Albumins - pharmacokinetics | Aged | Nanoparticles - administration & dosage | Antimitotic agents | Oncology, Experimental | Analysis | Breast cancer | Metastasis | Research | Antineoplastic agents | Cancer | Index Medicus
Journal Article
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 12/2015, Volume 76, Issue 6, pp. 1143 - 1152
Journal Article